<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940862</url>
  </required_header>
  <id_info>
    <org_study_id>Inno-6009</org_study_id>
    <nct_id>NCT00940862</nct_id>
  </id_info>
  <brief_title>Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovaderm Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Innovaderm Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the effect of adalimumab on inflammation of blood vessels that
      could lead to heart attack in patients with psoriasis. Changes to the carotid artery and
      ascending aorta will be evaluated in patients treated with adalimumab (systemic treatment)
      and compared against patients treated with a topical treatment that does not affect the
      entire body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis and rheumatoid arthritis (RA) have been shown to be independent risk factors for
      myocardial infarction (MI). The risk is believed to be related in part to systemic
      inflammation associated with these diseases. Some studies have suggested that treatment of RA
      patients with anti-TNF alpha can decrease the risks of MI. However, we do not have data on
      the effect of anti-TNF alpha on coronary atherosclerosis. Adalimumab is probably the best
      anti-TNF alpha candidate to study for an effect on coronary atherosclerosis as it has more
      affinity for membrane bound TNF alpha than other anti-TNF alpha products such as etanercept
      and a higher global anti-TNF alpha activity in psoriasis patients.

      This study involves a comparison of adalimumab administered sub-cutaneously with a loading
      dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week thereafter for a total
      of 10 injections (two 40 mg injections at week 0 for a total dose of 80 mg, followed by
      single injections at weeks 1, 3, 5, 7, 9, 11, 13 and 15) with non systemic treatments for
      psoriasis (topical therapy and/or UVB therapy). Patients will be randomized (2:1) to either
      adalimumab or topical and/or UVB therapy for psoriasis.

      If this pilot study shows that adalimumab reduces vascular inflammation in patients with
      psoriasis, a larger study could be undertaken to study the effect of adalimumab on coronary
      atherosclerotic plaques.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes in the target (atherosclerotic plaque) to background (blood) ratio (TBR) from the carotid artery and ascending aorta in patients randomized to adalimumab as compared to patients randomized to standard non-systemic therapy.</measure>
    <time_frame>Day -10 to -1, Day 105</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes in the TBR from a coronary artery from Day 0 to Day 105 in patients randomized to adalimumab as compared to patients randomized to standard therapy.</measure>
    <time_frame>Day -10 to -1, Day 105.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study changes in hs C-Reactive protein levels and serum lipids levels between Day 0 and Day 112 in patients randomized to adalimumab compared to patients randomized to standard therapy.</measure>
    <time_frame>Day 0, 28, 56, 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the safety of adalimumab in patients with psoriasis and history of coronary atherosclerosis or with at least three risk factors for coronary atherosclerosis. atherosclerosis or with at least three risk factors for coronary atherosclerosis</measure>
    <time_frame>Day 0, 28, 56, 112, 175</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the efficacy of adalimumab in patients with psoriasis and coronary atherosclerosis or at least three risk factors. PASI will be recorded and the percentage of patients achieving PASI 75 at Day 112 will be calculated for all patients randomized.</measure>
    <time_frame>Day 0, 28, 56, 112</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Psoriasis</condition>
  <condition>Vascular Inflammation</condition>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-systemic treatment.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)</description>
    <arm_group_label>adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVB Phototherapy</intervention_name>
    <description>This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.</description>
    <arm_group_label>Non-systemic treatment.</arm_group_label>
    <other_name>Ultra violet light B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical treatment</intervention_name>
    <description>This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:
Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids.</description>
    <arm_group_label>Non-systemic treatment.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old and capable of giving informed consent.

          -  at least a 6-month history of chronic moderate to severe psoriasis and a candidate for
             systemic therapy.

          -  BSA covered with psoriasis of at least 5 % or more at Baseline.

          -  An history of coronary atherosclerosis or at least three risk factors among the
             following: hypertension, active smoking, diabetes mellitus, dyslipidemia, obesity,
             microalbuminuria, age above 55 years, and first degree relative with coronary
             atherosclerosis before 65 years.

          -  Patient must be on a stable dose for at least 8 weeks before baseline if taking
             medications used to control angina, hypertension, serum lipids and any medication that
             can have an effect on inflammation.

          -  Patient has a carotid or ascending aorta atherosclerotic plaque inflammation target-to
             background ratio of 1.6 or more as determined by 18-FDG uptake measured by PET
             scanning.

          -  Female patient is either not of childbearing potential, defined as postmenopausal for
             at least 1 year or surgically sterile, or is of childbearing potential and practicing
             one of the following methods of birth control throughout the study and for 150 days
             after study completion:

               -  condoms, sponge, foams, jellies, diaphragm or IUD.

               -  contraceptives for three months prior to study drug administration

               -  a vasectomized partner.

          -  Female patient of childbearing potential must have a negative serum pregnancy test at
             the Screening visit.

          -  Patient is judged to be in good general health as determined by the principal
             investigator.

          -  Patient will be evaluated for latent TB infection with a PPD or a Quantiferon Gold
             test and CXR. Patient who demonstrates evidence of latent TB infection will only be
             allowed to participate in the study if they are willing to use TB prophylaxis
             according to Canadian guidelines

          -  Patient must be able and willing to provide written informed consent and comply with
             the requirements of this study protocol.

          -  Patient must be able and willing to self-administer SC injections or have a qualified
             person available to administer SC injections.

        Exclusion Criteria:

          -  Patient has other active skin diseases or skin infections (that may interfere with
             evaluation of psoriasis or with patient's safety.

          -  Patient has a history of an allergic reaction or significant sensitivity to
             constituents of study drug, including latex.

          -  Patient used any non-biological systemic therapy for the treatment of psoriasis less
             than 30 days before Day 0. Investigational chemical agents must be discontinued at
             least 30 days or five half-lives prior to the Baseline visit (whichever is longer).

          -  Patient who has used any biological therapy for the treatment of psoriasis less than 3
             months (90 days) before Day 0.

          -  Patient is taking or requires oral or injectable corticosteroids during the study.
             Inhaled corticosteroids for stable medical conditions are allowed.

          -  Patient has used any topical treatment for psoriasis or has used phototherapy within
             the last 2 weeks prior to baseline (at the exception of low strength (hydrocortisone
             and desonide) topical corticosteroid for the face, groin (including genitals) and
             inframammary areas).

          -  Patient has received Anakinra/Kineret within the last 2 weeks prior to the Baseline
             visit or is likely to receive Anakinra/Kineret during the course of the study.

          -  Patient has a poorly controlled medical condition, such as uncontrolled diabetes,
             documented history of recurrent infections, unstable ischemic heart disease,
             congestive heart failure a left ventricular ejection fraction of less than 40%, recent
             stroke, chronic leg ulcer or any other condition which, in the opinion of the
             investigator, would put the patient at risk if participating in the study.

          -  Patient had a myocardial infarction or hospitalization for a cardiac condition within
             the past 12 weeks.

          -  Patient has a history of acute coronary syndrome, percutaneous coronary intervention,
             coronary artery bypass graft, or carotid revascularization within 12 weeks of
             baseline.

          -  Patient for whom a change in medical treatment for angina, serum lipids, hypertension
             or any other medication that can have a significant effect on inflammation is planned
             for the duration of the study.

          -  Patient has a history of neurologic symptoms suggestive of central nervous system
             demyelinating disease.

          -  Patient has history of cancer or lymphoproliferative disease other than a successfully
             treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or
             localized carcinoma in situ of the cervix.

          -  Patient has a history of listeriosis, treated or untreated TB, persistent chronic
             infections, or recent active infections requiring hospitalization or treatment with
             intravenous anti-infectives within 30 days or oral anti-infectives within 14 days
             prior to the Baseline visit.

          -  Patient has received any live attenuated vaccine 28 days or less before baseline.

          -  Patient with hepatitis B or hepatitis C viral infection.

          -  Patient with any of the following: hemoglobin = 10 g/L, white blood cell count = 3.0 X
             109/L, platelet count =130 X 109/L, ALT = 2 times the upper limit of normal, AST = 2
             times the upper normal limit, total bilirubin = 2 times the upper normal limit or
             creatinine = 150 umol/L.

          -  Patient is currently using or plans to use anti-retroviral therapy at any time during
             the study.

          -  Patient is known to have immune deficiency or is immunocompromised.

          -  Female patient who is pregnant or breast-feeding or considering becoming pregnant
             during the study or for 150 days after the last dose of study medication.

          -  Patient has a history of clinically significant drug or alcohol abuse in the last
             year.

          -  Patient is considered by the investigator, for any reason, to be an unsuitable
             candidate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bissonnette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovaderm Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Claude Tardif, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S57-61. Review.</citation>
    <PMID>12894127</PMID>
  </reference>
  <reference>
    <citation>Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004 Nov;51(5):704-8.</citation>
    <PMID>15523347</PMID>
  </reference>
  <reference>
    <citation>Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002 Oct;47(4):512-8.</citation>
    <PMID>12271293</PMID>
  </reference>
  <reference>
    <citation>Tremblay JF, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg. 2002 May-Jun;6(3 Suppl):8-11. Epub 2002 Apr 30. Review.</citation>
    <PMID>11976984</PMID>
  </reference>
  <reference>
    <citation>Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg. 2004 Sep-Oct;8(5):321-37.</citation>
    <PMID>15868311</PMID>
  </reference>
  <reference>
    <citation>Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg. 2006;9 Suppl 1:18-25. Review.</citation>
    <PMID>16633860</PMID>
  </reference>
  <reference>
    <citation>Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41.</citation>
    <PMID>17032986</PMID>
  </reference>
  <reference>
    <citation>Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005 Nov;64(11):1595-601. Epub 2005 Apr 20.</citation>
    <PMID>15843450</PMID>
  </reference>
  <reference>
    <citation>Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005 Feb;52(2):402-11. Review.</citation>
    <PMID>15693010</PMID>
  </reference>
  <reference>
    <citation>Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003 Jun;30(6):1196-202.</citation>
    <PMID>12784389</PMID>
  </reference>
  <reference>
    <citation>van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2008 Jan;47(1):3-7. Epub 2007 Aug 16. Review.</citation>
    <PMID>17702769</PMID>
  </reference>
  <reference>
    <citation>Moubayed SP, Heinonen TM, Tardif JC. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol. 2007 Dec;18(6):638-44. Review.</citation>
    <PMID>17993809</PMID>
  </reference>
  <reference>
    <citation>Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis. 2007 Sep;66(9):1132-6. Epub 2007 Jan 24. Review.</citation>
    <PMID>17251223</PMID>
  </reference>
  <reference>
    <citation>Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007 Sep;56(9):2905-12.</citation>
    <PMID>17763428</PMID>
  </reference>
  <reference>
    <citation>Jacobsson LT, Turesson C, GÃ¼lfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005 Jul;32(7):1213-8.</citation>
    <PMID>15996054</PMID>
  </reference>
  <reference>
    <citation>Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014-22.</citation>
    <PMID>14627786</PMID>
  </reference>
  <reference>
    <citation>Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1):106-15. Epub 2007 Oct 23.</citation>
    <PMID>17936411</PMID>
  </reference>
  <reference>
    <citation>Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005 Jun;152(6):1304-12.</citation>
    <PMID>15948997</PMID>
  </reference>
  <reference>
    <citation>Choi SH, Chae A, Chen CH, Merki E, Shaw PX, Tsimikas S. Emerging approaches for imaging vulnerable plaques in patients. Curr Opin Biotechnol. 2007 Feb;18(1):73-82. Epub 2007 Jan 17. Review.</citation>
    <PMID>17234398</PMID>
  </reference>
  <reference>
    <citation>Di Carli MF, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation. 2007 Mar 20;115(11):1464-80. Review.</citation>
    <PMID>17372188</PMID>
  </reference>
  <reference>
    <citation>Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006 Jun 27;113(25):2936-42.</citation>
    <PMID>16801474</PMID>
  </reference>
  <reference>
    <citation>Horiguchi J, Fujioka C, Kiguchi M, Shen Y, Althoff CE, Yamamoto H, Ito K. Soft and intermediate plaques in coronary arteries: how accurately can we measure CT attenuation using 64-MDCT? AJR Am J Roentgenol. 2007 Oct;189(4):981-8.</citation>
    <PMID>17885074</PMID>
  </reference>
  <reference>
    <citation>Oncel D, Oncel G, Tastan A, Tamci B. Detection of significant coronary artery stenosis with 64-section MDCT angiography. Eur J Radiol. 2007 Jun;62(3):394-405. Epub 2007 Feb 15.</citation>
    <PMID>17306490</PMID>
  </reference>
  <reference>
    <citation>Pohle K, Achenbach S, Macneill B, Ropers D, Ferencik M, Moselewski F, Hoffmann U, Brady TJ, Jang IK, Daniel WG. Characterization of non-calcified coronary atherosclerotic plaque by multi-detector row CT: comparison to IVUS. Atherosclerosis. 2007 Jan;190(1):174-80. Epub 2006 Feb 21.</citation>
    <PMID>16494883</PMID>
  </reference>
  <reference>
    <citation>Gould KL. Positron emission tomography in coronary artery disease. Curr Opin Cardiol. 2007 Sep;22(5):422-8. Review.</citation>
    <PMID>17762543</PMID>
  </reference>
  <reference>
    <citation>Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. Review.</citation>
    <PMID>15843671</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>vascular inflammation</keyword>
  <keyword>coronary atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

